Search

ACADIA Pharmaceuticals Inc

Closed

SectorHealthcare

25.61 -1.12

Overview

Share price change

24h

Current

Min

25.13

Max

26.05

Key metrics

By Trading Economics

Income

-270M

3.6M

Sales

-16M

268M

P/E

Sector Avg

11.864

60.149

EPS

0.02

Profit margin

1.357

Employees

796

EBITDA

-19M

7M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+26.36% upside

Dividends

By Acuity

Next Earnings

5 Aug 2026

Market Stats

By TradingEconomics

Market Cap

691M

4.5B

Previous open

26.73

Previous close

25.61

News Sentiment

By Acuity

39%

61%

118 / 342 Healthcare

ACADIA Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Jul 2026, 23:52 UTC

Correlated Moves
Social Media
News

Western Digital shares fell after hours, closing at about $513.97. Option traders showed bearish sentiment, with puts outpacing calls in volume.

15 Jul 2026, 23:26 UTC

News

Synopsys shares are higher in after-market hours following a Buy rating from analyst Gary Mobley, who set a price target of $570.

15 Jul 2026, 23:16 UTC

Social Media
News

PayPal Holdings Inc. shares are lower in after-market trading amid uncertainty over a $53 billion acquisition offer from Stripe and Advent International.

15 Jul 2026, 23:11 UTC

Correlated Moves
News

The CHF/HKD exchange rate is trading higher, influenced by a decline in the US Producer Price Index and a stronger NY Empire State Manufacturing Index.

15 Jul 2026, 23:06 UTC

Social Media
News

Wedbush initiates coverage on eBay with an Outperform rating. Shares are higher in after-hours trading following positive sentiment and acquisition news.

15 Jul 2026, 23:06 UTC

News

American Airlines Group shares are lower in after-market hours following the appointment of John W. Dietrich to its board amid rising fuel price concerns.

15 Jul 2026, 23:06 UTC

News

Vanguard Total Bond Market ETF is slightly higher in after-market hours, reflecting cautious investor sentiment amid escalating Middle East tensions and oil supply concerns.

15 Jul 2026, 23:02 UTC

News
Social Media
Event

United Airlines Holdings shares fell in after-hours trading despite reporting strong second-quarter earnings of $1.99 per share and revenue of $17.67 billion.

15 Jul 2026, 23:01 UTC

Social Media
News

J.B. Hunt Transport Services shares rose in after-market trading following strong second-quarter results, with revenues up 19% to $3.50 billion and EPS of $1.91.

15 Jul 2026, 23:01 UTC

News

Wedbush initiated coverage on Booking Holdings with an Outperform rating. Shares are higher in after-market trading following a close at $174.85.

15 Jul 2026, 22:16 UTC

News

Micron Technology will participate in the KeyBanc Capital Markets Technology Leadership Forum on August 10, 2026. Shares are higher in after-hours trading.

15 Jul 2026, 20:14 UTC

ETF Constituents
News
Correlated Moves

The Vanguard Large-Cap ETF is lower in after-market hours, influenced by slight declines in major holdings like Microsoft and Apple amid mixed U.S. equity performance.

15 Jul 2026, 20:07 UTC

News

Bitcoin's price is declining amid broader market sentiment shifts following softer inflation readings. Geopolitical tensions may also be influencing the cryptocurrency market.

15 Jul 2026, 20:07 UTC

News
Correlated Moves

Microchip Technology shares are lower today, following a broader Nasdaq decline. Ongoing U.S.-Iran tensions continue to affect overall investor sentiment.

15 Jul 2026, 20:07 UTC

News

Ethereum is trading higher, continuing an upward trend since Tuesday. The U.S. Producer Price Index decline has eased inflation concerns and boosted market sentiment.

15 Jul 2026, 20:07 UTC

News

Bitcoin's price is lower today, influenced by softer inflation data and ongoing geopolitical tensions, despite earlier gains above Tuesday's close.

15 Jul 2026, 20:06 UTC

News

Charter Communications shares rose following Liberty Broadband's $17.65 million insider sale of 129,907 shares, despite a recent revenue decline.

15 Jul 2026, 20:03 UTC

Social Media
News

Amazon.com Inc is higher today, driven by a partnership with Herotel for satellite internet services and leadership changes within Amazon Web Services.

15 Jul 2026, 20:02 UTC

Social Media
News
Macro Event

CSX shares are lower as Benchmark cuts its price target to $4 from $48, while Citizens initiates coverage with a Market Perform rating.

15 Jul 2026, 20:02 UTC

News

Cisco Systems Inc shares are lower, hitting a nine-week low of 111.29 USD amid a broader decline in the Communications Equipment sub-sector.

15 Jul 2026, 20:02 UTC

News

Workday Inc. shares are higher, supported by positive sentiment after a drop in the U.S. Producer Price Index, easing inflation concerns and interest rate hike expectations.

15 Jul 2026, 20:02 UTC

Social Media
News

Apple Inc. shares rose after regulatory approval for its generative AI service in China and Citibank's price target increase to $365 amid market challenges.

15 Jul 2026, 20:02 UTC

Correlated Moves
News
Macro Event
Social Media

Lam Research shares are lower as the Semiconductor Materials & Equipment sector declines. UBS raised its price target to $435, despite negative sentiment from insider selling.

15 Jul 2026, 20:02 UTC

Social Media
Macro Event
Event
News

Cintas Corp's stock rises following strong fiscal fourth-quarter results, with revenue of $2.91 billion and GAAP EPS of $1.26 exceeding analyst expectations.

15 Jul 2026, 20:02 UTC

Correlated Moves
Social Media
Macro Event
News

Applied Materials Inc shares are lower today amid mixed assessments, despite UBS raising its price target to $705. The stock's recent surge raises investor caution.

15 Jul 2026, 19:56 UTC

News
Social Media

Broadcom faces EU scrutiny over VMware practices, yet shares are higher amid positive sentiment for hardware makers and AI demand.

15 Jul 2026, 19:56 UTC

News
Social Media

MercadoLibre shares are lower as Bronstein, Gewirtz & Grossman, LLC announces an investigation into potential claims following extended loan term disclosures.

15 Jul 2026, 19:56 UTC

News

Electronic Arts is rising amid reports of increased confidence in regulatory approval for its $55 billion acquisition at $210 per share.

15 Jul 2026, 19:53 UTC

News
Social Media
Macro Event

Microsoft shares are higher today as Evercore ISI raised its price target to $525. Analysts remain optimistic ahead of the upcoming earnings report.

15 Jul 2026, 19:52 UTC

News
Social Media

Alphabet Inc shares are higher, boosted by Warren Buffett's endorsement and plans for third-party stores in its App Store. Anticipation for earnings also supports momentum.

Peer Comparison

Price change

ACADIA Pharmaceuticals Inc Forecast

Price Target

By TipRanks

26.36% upside

12 Months Forecast

Average 32.21 USD  26.36%

High 38 USD

Low 23 USD

Based on 15 Wall Street analysts offering 12 month price targets forACADIA Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

11

Buy

4

Hold

0

Sell

Sentiment

By Acuity

118 / 342 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat